解开大自然隐藏的宝藏:放线菌的有效抗病毒化合物库对抗人类病毒感染。

IF 3.5 3区 医学 Q3 IMMUNOLOGY
Microbial pathogenesis Pub Date : 2025-11-01 Epub Date: 2025-08-05 DOI:10.1016/j.micpath.2025.107953
By Lina Amrani, Nurin Sabrina Zawari, Nur Zahirah Afrina Abd Rahman, Adzzie Shazleen Azman, Nurshamimi Nor Rashid, Jasmine Elanie Khairat
{"title":"解开大自然隐藏的宝藏:放线菌的有效抗病毒化合物库对抗人类病毒感染。","authors":"By Lina Amrani, Nurin Sabrina Zawari, Nur Zahirah Afrina Abd Rahman, Adzzie Shazleen Azman, Nurshamimi Nor Rashid, Jasmine Elanie Khairat","doi":"10.1016/j.micpath.2025.107953","DOIUrl":null,"url":null,"abstract":"<p><p>The global emergence of infectious diseases, including COVID-19, Mpox, MERS, Ebola, dengue, Zika, and avian influenza, alongside the escalation of antimicrobial resistance, has made the discovery of novel antiviral agents an urgent priority. Actinomycetota, a diverse group of microorganisms known for their medicinal properties and antibiotic production, stand out as a promising source of antiviral compounds. Since the 20th century, studies on the antiviral potential of Actinomycetota-derived secondary metabolites have shown efficacy against various human viruses, such as influenza viruses (IVs), human coronaviruses (hCoVs), respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), mosquito-borne viruses such as Zika virusZIKV), dengue virus (DENV), West Nile virus (WNV), Chikungunya virus (CHIKV)), and monkeypox virus (MPXV). This review provides a comprehensive summary of key findings from the literature, emphasizing the theurapeutic potential of these compounds and the importance of further research to elucidate their mechanisms of action and enhance their production. Unlocking the antiviral arsenal of Actinomycetota may pave the way for the development of novel and effective antiviral therapies to combat human viral diseases.</p>","PeriodicalId":18599,"journal":{"name":"Microbial pathogenesis","volume":" ","pages":"107953"},"PeriodicalIF":3.5000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unlocking nature's hidden treasures: Actinomycetota's arsenal of potent antiviral compounds against human viral infections.\",\"authors\":\"By Lina Amrani, Nurin Sabrina Zawari, Nur Zahirah Afrina Abd Rahman, Adzzie Shazleen Azman, Nurshamimi Nor Rashid, Jasmine Elanie Khairat\",\"doi\":\"10.1016/j.micpath.2025.107953\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The global emergence of infectious diseases, including COVID-19, Mpox, MERS, Ebola, dengue, Zika, and avian influenza, alongside the escalation of antimicrobial resistance, has made the discovery of novel antiviral agents an urgent priority. Actinomycetota, a diverse group of microorganisms known for their medicinal properties and antibiotic production, stand out as a promising source of antiviral compounds. Since the 20th century, studies on the antiviral potential of Actinomycetota-derived secondary metabolites have shown efficacy against various human viruses, such as influenza viruses (IVs), human coronaviruses (hCoVs), respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), mosquito-borne viruses such as Zika virusZIKV), dengue virus (DENV), West Nile virus (WNV), Chikungunya virus (CHIKV)), and monkeypox virus (MPXV). This review provides a comprehensive summary of key findings from the literature, emphasizing the theurapeutic potential of these compounds and the importance of further research to elucidate their mechanisms of action and enhance their production. Unlocking the antiviral arsenal of Actinomycetota may pave the way for the development of novel and effective antiviral therapies to combat human viral diseases.</p>\",\"PeriodicalId\":18599,\"journal\":{\"name\":\"Microbial pathogenesis\",\"volume\":\" \",\"pages\":\"107953\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Microbial pathogenesis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.micpath.2025.107953\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial pathogenesis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.micpath.2025.107953","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

全球传染病的出现,包括COVID-19、Mpox、MERS、埃博拉、登革热、寨卡和禽流感,以及抗菌素耐药性的升级,使得发现新的抗病毒药物成为当务之急。放线菌是一组以其药用特性和抗生素生产而闻名的微生物,作为抗病毒化合物的有前途的来源而脱颖而出。自20世纪以来,对放线菌衍生的次级代谢物的抗病毒潜力的研究表明,放线菌衍生的次级代谢物对多种人类病毒,如流感病毒(IVs)、人类冠状病毒(hcov)、呼吸道合胞病毒(RSV)、人类免疫缺陷病毒(HIV)、单纯疱疹病毒(HSV)、蚊媒病毒如寨卡病毒(zikv)、登革热病毒(DENV)、西尼罗河病毒(WNV)、基孔肯雅病毒(CHIKV)和猴痘病毒(MPXV)具有抗病毒作用。本文综述了文献中的主要发现,强调了这些化合物的治疗潜力,以及进一步研究阐明其作用机制和提高其生产的重要性。释放放线菌的抗病毒武器库可能为开发新的有效的抗病毒疗法来对抗人类病毒性疾病铺平道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Unlocking nature's hidden treasures: Actinomycetota's arsenal of potent antiviral compounds against human viral infections.

The global emergence of infectious diseases, including COVID-19, Mpox, MERS, Ebola, dengue, Zika, and avian influenza, alongside the escalation of antimicrobial resistance, has made the discovery of novel antiviral agents an urgent priority. Actinomycetota, a diverse group of microorganisms known for their medicinal properties and antibiotic production, stand out as a promising source of antiviral compounds. Since the 20th century, studies on the antiviral potential of Actinomycetota-derived secondary metabolites have shown efficacy against various human viruses, such as influenza viruses (IVs), human coronaviruses (hCoVs), respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), mosquito-borne viruses such as Zika virusZIKV), dengue virus (DENV), West Nile virus (WNV), Chikungunya virus (CHIKV)), and monkeypox virus (MPXV). This review provides a comprehensive summary of key findings from the literature, emphasizing the theurapeutic potential of these compounds and the importance of further research to elucidate their mechanisms of action and enhance their production. Unlocking the antiviral arsenal of Actinomycetota may pave the way for the development of novel and effective antiviral therapies to combat human viral diseases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Microbial pathogenesis
Microbial pathogenesis 医学-免疫学
CiteScore
7.40
自引率
2.60%
发文量
472
审稿时长
56 days
期刊介绍: Microbial Pathogenesis publishes original contributions and reviews about the molecular and cellular mechanisms of infectious diseases. It covers microbiology, host-pathogen interaction and immunology related to infectious agents, including bacteria, fungi, viruses and protozoa. It also accepts papers in the field of clinical microbiology, with the exception of case reports. Research Areas Include: -Pathogenesis -Virulence factors -Host susceptibility or resistance -Immune mechanisms -Identification, cloning and sequencing of relevant genes -Genetic studies -Viruses, prokaryotic organisms and protozoa -Microbiota -Systems biology related to infectious diseases -Targets for vaccine design (pre-clinical studies)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信